Clinical trial NCT00131456: Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1
Official title: Marijuana Addiction and Depression: Venlafaxine Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Depression
Marijuana Abuse
Keywords: cannabis dependence
depression
treatment
venlafaxine
Lead sponsor: New York State Psychiatric Institute
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2005-08-18
Enrollment: 123
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if Venlafaxine Extended Release (Ven-XR) is effective in treating individuals with marijuana addiction and depression.

Detailed description: Given that depression and marijuana addiction often occur together, medications to treat individuals diagnosed with both conditions may be effective. The purpose of this study is to determine the effectiveness of Ven-XR in treating individuals diagnosed with depression and marijuana addiction.

During this twelve-week, double-blind, placebo-controlled study, study visits will occur twice each week. During study visits, participants will receive either placebo or medication and provide a urine sample for drug screening. Blood tests will be collected each month and women must take pregnancy tests each month. Throughout the study, all participants will receive individualized psychotherapy sessions. At each study visit, participants will be given $5 to cover transportation costs.

Eligibility criteria: Inclusion Criteria:

* Meets criteria for current marijuana addiction and reports marijuana as primary drug of abuse
* Currently meets criteria for major depression or dysthymic disorder and receive a score of greater than or equal to 12 on the Hamilton Depression Inventory
* Clinically depressed for at least 3 months during a period of active marijuana use
* Women of child-bearing age will be included provided that they are not pregnant, based on the results of a blood pregnancy done at the time of screening and agree to use a method of contraception with proven efficacy and not to become pregnant during the study. To confirm this, blood pregnancy tests will be repeated monthly. Women will be provided a full explanation of the potential dangers of pregnancy while on the study. If a woman becomes pregnant, the study medication will be discontinued.

Exclusion Criteria:

* Meets criteria for past manic or psychotic disorder, unless substance-related
* History of a seizure disorder
* Individuals with chronic organic mental syndrome
* Any significant risk for suicide based on current assessment and history of attempts
* History of allergic reaction to either Venlafaxine or Ven-XR
* Unstable physical disorders that might make participation hazardous, such as uncontrolled hypertension and tachycardia (SBP\>150, DBP \>90, or a sitting quietly HR\>100), acute hepatitis (patients with chronic mildly elevated transaminase levels (\<2x upper limit of normal are acceptable) or unstable diabetes
* History of failure to respond to a previous adequate trial of Venlafaxine of at least 300 mg. for at least a 6-week period
* Physical dependence on any other drugs (excluding nicotine) that would require medical detoxification
* Currently being prescribed psychotropic medication by another physician (in the last 3 weeks), except for acute treatment of insomnia.
* Pregnant or breast-feeding

Primary outcomes:
measure: Two Consecutive Weeks of Marijuana Abstinence
timeFrame: measured daily by self report for 12 weeks of the trial or length of study participation
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York State Psychiatric Institute
state: New York
Study officials:
affiliation: New York State Psychiatric Institute
name: Frances R Levin, M.D.
role: PRINCIPAL_INVESTIGATOR
References: